We describe an 18-year-old woman infected with H1N1 influenza followed by thrombotic microangiopathy. During the acute phase, her plasma levels of von Willebrand factor (VWF) were remarkably elevated, whereas those of ADAMTS13 were reduced without its inhibitors, generating a markedly high ratio of VWF to ADAMTS13 in circulation. A retrospective analysis established the following hypothesis: an influenzamediated cytokine storm induced an enhanced release of unusually large VWF multimers (UL-VWFM) from vascular endothelial cells, generating platelet thrombi in microcirculatures under high shear stress. Plasma exchange removed UL-VWFM and cytokines, and rescued her life. This report sheds a light on a hitherto unrecognized influenza complication.
Introduction
Thrombotic microangiopathies (TMAs) are pathological conditions, characterized by organ dysfunction due to platelet thrombi in the microvasculature, consumptive thrombocytopenia, and microangiopathic hemolytic anemia (MAHA). Two typical phenotypes of TMAs are thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic syndrome (HUS) (1) . But, other diseases such as HELLP syndrome (hemolysis, elevated liver enzymes, and low platelet syndrome) associated with pregnancy-induced hypertension are also included in a category of TMA.
ADAMTS13 (a disintegrin-like and metalloproteinase with thrombospondin type 1 motif, member 13) is a metalloprotease which specifically cleaves the Tyr1605-Met1606 bond in the von Willebrand factor (VWF) A2 domain (2) . In the absence of ADAMTS13 activity (ADAMTS13: AC), unusually large VWF multimers (UL-VWFM) released from vascular endothelial cells (EC) are not appropriately cleaved, accumulate in circulation, and induce generalized formation of platelet thrombi in the microvasculature under conditions of high shear stress. This results in TTP, a life-threatening disease. Currently, a severe deficiency of ADAMTS13: AC due to the genetic mutations or acquired autoantibodies is thought to be a specific feature for TTP (3) .
The accumulation of UL-VWFM in the circulation is alternatively achieved under conditions of an extremely low enzyme-to-substrate (E/S) ratio, when the plasma level of UL-VWFM is substantially higher than that of ADAMTS13, which is mainly produced in the liver (4). This scenario often occurs when there are high plasma levels of cytokines such as interleukin (IL)-6 and its receptor complex, IL-8, and tumor necrosis factor (TNF)-α. This condition, termed cytokine storm, which stimulates the release of UL-VWFM from vascular EC (5), can develop in the context of connective tissue disease, organ transplantation, and sepsis. In these clinical settings, a pathological diagnosis of TMA is often used in clinical practice (6) .
In 1981, Wasserstein et al (7) described the first case of recurrent TTP in association with influenza. The pathological diagnosis was made by renal biopsy findings with features of chronic renal disease: glomeruli with thickened capillary walls and numerous 'double contours,' as well as several hyaline capillary thrombi, accompanied by MAHA and thrombocytopenia. However, there have been no subsequent reports of influenza-induced TTP described since, except for cases of influenza vaccine-associated TTP (8, 9) . We previously identified a 68-year-old woman with influenza Aassociated TTP who had severe ADAMTS13: AC deficiency due to the production of neutralizing IgG-inhibitors (10), but we suggested that the frequency of this phenomenon is far less common. Here, we describe an 18-year-old woman with H1N1 influenza who developed TMA with a mild reduction of plasma ADAMTS13 activity (ADAMTS13: AC) without ADAMTS 13-neutralizing autoantibodies ( inhibitors ) (ADAMTS13: INH), and was successfully treated with plasma exchange (PE). A retrospective analysis of plasma VWF and VWF multimers may address how influenzainduced TMA, a hitherto unrecognized complication, developed in this patient and why PE was effective.
Case Report
Clinical course: An 18-year-old woman presented to our institution, Matsudo City Hospital, with gross hematuria and massive epistaxis in August, 2009. Two days earlier she visited a nearby clinic complaining of fever and chills, where she was diagnosed with influenza and received a prescription for zanamivir 20 mg daily for 2 days. At age 4 she had an episode of atypical hemolytic uremic syndrome (HUS) associated with influenza A infection which was successfully treated by three courses of PE but she had no subsequent episodes.
On physical examination, the patient was afebrile (37.2 ). Her heart rate was 85 beats per minute and regular, blood pressure 121/78 mmHg, respiration rate 18 breaths per minute and regular. She was alert, without any disturbances in consciousness. There were no apparent signs of bruising. The results of laboratory testing on hospital day (HD) 1-3 are shown in Table 1 . Of note, prothrombin time (PT) and activated prothrombin time (A-PTT) on HD1 were within the normal ranges, but two markers of disseminated intravascular coagulation (DIC), fibrinogen degradation products (FDP) and D-dimer, were slightly increased. Thus, by the diagnostic criteria for DIC from the International Society of Thrombosis and Haemostasis (11) and from the Japanese Ministry of Health and Welfare (12), the patient had a DIC score of 4 (non-overt DIC) and 7 (overt DIC), respectively. On the other hand, the patient's plasma level of VWF antigen (VWF: Ag) was increased (191% of normal), and that of ADAMTS13: AC determined by chromogenic act-ELISA (13) was significantly reduced (37% of normal) with a marginal level of ADAMTS13: INH (0.7 Bethesda U/ mL). These results suggested that a diagnosis of TMA was preferable to TTP. Thus, on admission a differential diagnosis of DIC or TMA was not readily suggested. In fact, through the following clinical course, plasma levels of fibrinogen, PT, and A-PTT were within the normal range, however the high plasma levels of VWF: Ag and low levels of ADAMTS13: AC were consistently noted during the acute phase. Together with these results, the characteristic clinical features, such as MAHA, thrombocytopenia and renal dysfunction, a diagnosis of influenza-associated TMA rather than DIC was made. The H1N1 influenza infection was confirmed on HD 2 by genotyping.
The timing of various therapeutic interventions and relevant laboratory data trends are shown in Fig. 1A . The patient was initially treated with an infusion of 480 mL of fresh frozen plasma (FFP). Since there was no appreciable clinical improvement, we next initiated PE, which was performed on a total of 4 days (HD 2-4 and HD 6), with a single daily plasma dose of 3,000-4,200 mL. Red blood cell concentrates (RCC) were also infused with a total volume of 420 mL on HD 5, but no platelets were administered. Since no distinct anti-ADAMTS13: INH were detected, steroid therapy was not initiated. Platelet counts began to increase on HD 5 and reached the normal range on HD 9, along with the patient's clinical condition and laboratory data for MAHA and renal function. Renal biopsy performed on HD 18 showed signs of vascular endothelial cell injury, namely focal segmental endocapillary proliferative glomerulonephritis with focal segmental double contours (figure not shown).
Sequential VWF multimer analysis during the clinical course: A retrospective analysis of VWFM by vertical SDSagarose gel electrophoresis (14) was performed using plasma samples stored at -80 . As shown in Fig. 1B , plasma levels of VWF: Ag were significantly elevated during the acute phase (HD 1-7) with a uniquely and dynamically changed multimer profile. On HD 1 the plasma VWF: Ag level was elevated but lacked High molecular weight (HMW) forms. We identified an extremely high level of plasma VWF: Ag on HD 4 and 7 along with the appearance of UL-VWFM. In sharp contrast, on HD 3 and 6, UL-VWFM and HMW-VWFM were undetectable. During the recovery stage (HD 9-23) the VWFM pattern normalized and became almost indistinguishable. Plasma levels of the cytokines IL-6, IL-8, and TNF-α, were also analyzed and found to be remarkably elevated on admission.
Discussion
Although this patient had a history of atypical HUS at age 4, she did not have any further episodes during the subsequent 14 years. It is currently recognized that there is a late-onset form of congenital ADAMTS13: AC deficiency called Upshaw-Schulman syndrome (15) . However, this possibility was excluded by the measurement of ADAMTS13: AC on this occasion. Another possibility which remains is that the patient has TMA-predisposing genetic defects in complement regulatory proteins, such as factor H, factor I, (16) . However, if she had such an underlying defect, she would likely have severe renal impairment, whereas her renal dysfunction was marginal and transient; thus, it is less likely she had such genetic defects.
We have recently proposed a model for the pathogenesis of TMA, in which an extremely low circulating E/S (ADAMTS13/VWF) ratio is sufficient to cause TMA under certain rheological conditions, such as high shear stress (6). This hypothesis was drawn from previous reports (5), in which VWF release from vascular EC is upregulated in vitro by cytokines such as IL-6 (and its receptor complex), IL-8, and TNF-α, and plasma ADAMTS13: AC is thereby compensatively consumed. This further aggravates the low E/S (ADAMTS13/UL-VWFM) ratio while generating platelet thrombi in the microcirculation. Influenza viremia stimulates monocytes to release cytokines, which can result in severe cytokinemia, or cytokine storm.
To test this hypothesis, here we performed a retrospective analysis of cytokine and VWFM levels in this patient. The plasma levels of IL-6, IL-8, and TNF-α, were indeed markedly increased. Most interestingly, however, a striking change was seen in the plasma levels of VWF: Ag, which were significantly elevated during the acute phase (HD 1-7) with a uniquely and dynamically changed multimeric pattern (Fig. 1B) . In particular, the selective absence of UL-and HMW-VWFM under these circumstances might be attributable to the reduced production or increased removal from and/or degradation in the circulation. The former mechanism is less likely, because the cytokinemia observed in influenza patients during the acute phase continuously stimulates VWF release from vascular EC. Furthermore, to cleave the newly-released UL-/HMW-VWFM, plasma ADAMTS13: AC is vigorously consumed. The mild reduction of ADAMTS13: AC seen here, therefore, appears to be a reflection of this reaction. As for the latter mechanism, the circulating UL-/HMW-VWFM is consumed when it func- tions as a molecular glue that facilitates platelet hyperaggregation or thrombi formation. These explanations may address the co-existence of undetectable UL-/HMW-VWFM and a mild reduction of ADAMTS13: AC in the same patient. In line with this scenario, during the recovery stage on HD 9-23 the VWFM patterns became normal and almost indistinguishable from each other.
If the extensive analyses on VWF and ADAMTS13 had not been performed, the patient in this study might have had a diagnosis of flu-associated DIC, according to the previous diagnostic criteria (11, 12) . In fact, TMAs are pathologically featured by platelet thrombi and DIC by fibrin thrombi, each formed in microvasculatures. Thus, it is conceivable that TMA is further complicated by DIC and both clinical conditions may co-exist, but its reversal clinical course appears to be less likely. Thus, the most important finding in this study is the markedly high plasma ratio of VWF to ADAMTS13, as seen in swine flu patients, that may induce microcirculatory disturbance by platelet thrombi under high shear-stress, a hitherto unrecognized flu complication.
From another point of view, the desialyation of VWF by influenza viral neuraminidase may play a role. The carbohydrate-and sialic acid-rich VWF, once desialylated by neuraminidase, can bind to platelet glycoprotein Ib and induce platelet aggregation (17, 18) . This was left unaddressed here since the level of sialyation in the patient's VWF was not assessed; future studies should address this possibility.
In conclusion, we propose that TMA is induced by influenza infection through the following mechanism. First, the release of UL-VWFM from vascular EC is enhanced by stimulation with cytokinemia induced by influenza infection. Second, elevated levels of plasma UL-and HMW-VWFM mediate platelet hyperaggregation and thrombi formation in the microvasculature. Third, the formed platelet thrombi can cause dysfunction in various organs, typically renal insufficiency. PE is a highly effective treatment for influenzainduced TMA by reducing plasma levels of cytokines and UL-/HMW-VWFM and through replenishing VWFM and ADAMTS13.
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